KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Bio-Rad Laboratories (BIO) Accumulated Depreciation & Amortization (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Accumulated Depreciation & Amortization for 17 consecutive years, with $165.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 9.1% to $165.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $165.4 million, a 9.1% increase, with the full-year FY2025 number at $165.4 million, up 9.1% from a year prior.
  • Accumulated Depreciation & Amortization was $165.4 million for Q4 2025 at Bio-Rad Laboratories, up from $151.6 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $1.1 billion in Q2 2023 to a low of $137.3 million in Q4 2022.
  • A 5-year average of $570.1 million and a median of $551.5 million in 2021 define the central range for Accumulated Depreciation & Amortization.
  • Biggest YoY gain for Accumulated Depreciation & Amortization was 2690.39% in 2021; the steepest drop was 0.72% in 2021.
  • Bio-Rad Laboratories' Accumulated Depreciation & Amortization stood at $137.6 million in 2021, then fell by 0.22% to $137.3 million in 2022, then rose by 6.26% to $145.9 million in 2023, then rose by 3.91% to $151.6 million in 2024, then rose by 9.1% to $165.4 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Accumulated Depreciation & Amortization are $165.4 million (Q4 2025), $151.6 million (Q4 2024), and $145.9 million (Q4 2023).